Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 19/20 | 0.58 |
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | MMP14 | P50281 | 3/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21582804 | 0.80 | ADAMTS5 (0.73) | ADAMTS5MMP2MMP14ADAMTS4 | |
| SCHEMBL17871444 | 0.80 | ADAMTS5 (0.55) | ADAMTS5MMP2MMP14ADAMTS4 | |
| SCHEMBL19976094 | 0.76 | ADAMTS5 (0.65) | ADAMTS5MMP2MMP14 | |
| SCHEMBL17871537 | 0.73 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP14ADAMTS4 | |
| Aldumastat SCHEMBL17871211 | 0.73 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP14ADAMTS4 | |
| Aldumastat SCHEMBL17871325 | 0.73 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP14ADAMTS4 | |
| Aldumastat SCHEMBL17884630 | 0.73 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP14ADAMTS4 | |
| SCHEMBL30609664 | 0.73 | ADAMTS5 (0.64) | ADAMTS5MMP2MMP14ADAMTS4 | |
| SCHEMBL17884967 | 0.73 | ADAMTS5 (0.64) | ADAMTS5MMP2MMP14ADAMTS4 | |
| SCHEMBL20708257 | 0.72 | ADAMTS5 (0.69) | ADAMTS5MMP2MMP14ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124424-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | GALAPAGOS NV (BE) | 2024-04-18 | — | — | US | claimed |
| EP-4263530-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | claimed |
| CN-116723840-A | Solid forms of (5S) -cyclopropyl-5- [3- [ (3S) -4- (3, 5-difluorophenyl) -3-methyl-piperazin-1-yl ] -3-oxo-propyl ] imidazolidine-2, 4-dione | 加拉帕戈斯股份有限公司 | 2023-09-08 | — | — | CN | claimed |
| WO-2022128849-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | claimed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | claimed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | claimed |
| EP-3237406-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Galapagos NV (BE) | 2017-11-01 | — | — | EP | claimed |
| WO-2016102347-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2016-06-30 | — | — | WO | claimed |
| US-20240124424-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | GALAPAGOS NV (BE) | 2024-04-18 | — | — | US | disclosed |
| US-20240124424-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | GALAPAGOS NV (BE) | 2024-04-18 | — | — | US | disclosed |
| EP-4263530-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-116723840-A | Solid forms of (5S) -cyclopropyl-5- [3- [ (3S) -4- (3, 5-difluorophenyl) -3-methyl-piperazin-1-yl ] -3-oxo-propyl ] imidazolidine-2, 4-dione | 加拉帕戈斯股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116723840-A | Solid forms of (5S) -cyclopropyl-5- [3- [ (3S) -4- (3, 5-difluorophenyl) -3-methyl-piperazin-1-yl ] -3-oxo-propyl ] imidazolidine-2, 4-dione | 加拉帕戈斯股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116723840-A | Solid forms of (5S) -cyclopropyl-5- [3- [ (3S) -4- (3, 5-difluorophenyl) -3-methyl-piperazin-1-yl ] -3-oxo-propyl ] imidazolidine-2, 4-dione | 加拉帕戈斯股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| WO-2022128849-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| EP-3237406-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Galapagos NV (BE) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102347-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124424-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | COL2A1, COL1A1, COL14A1 | ADAMTS5 21/4885MMP2 180/4885MMP14 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.